Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests ribociclib combo to stop breast cancer return

NCT ID NCT06930859

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well ribociclib, a targeted cancer drug, works when added to hormone therapy for people with HR+ HER2- stage II or III breast cancer. It will follow about 2,766 patients in Russia, comparing those who get ribociclib plus hormone therapy to those who got hormone therapy alone in the past. The goal is to see if the combination helps prevent the cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ribociclib (a targeted cancer drug) combined with hormone therapy (letrozole or anastrozole)
What this could lead to
If successful, this could show that adding ribociclib to standard hormone therapy helps prevent breast cancer from coming back in people with HR+ HER2- stage II or III cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It's also early in real-world use, and side effects like low blood cell counts or liver issues are possible with ribociclib.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Kaluga, Russia, 248007, Russia

  • Novartis Investigative Site

    RECRUITING

    Pskov, Russia, 180000, Russia

  • Novartis Investigative Site

    RECRUITING

    Ryazan, Russia, 390011, Russia

  • Novartis Investigative Site

    RECRUITING

    Saint Petersburg, Russia, 197758, Russia

  • Novartis Investigative Site

    RECRUITING

    Surgut, Tymen Area, 628402, Russia

  • Novartis Investigative Site

    RECRUITING

    Arkhangelsk, 163045, Russia

  • Novartis Investigative Site

    RECRUITING

    Barnaul, 656045, Russia

  • Novartis Investigative Site

    RECRUITING

    Bryansk, 241028, Russia

  • Novartis Investigative Site

    RECRUITING

    Irkutsk, 664035, Russia

  • Novartis Investigative Site

    RECRUITING

    Ivanovo, 153040, Russia

  • Novartis Investigative Site

    RECRUITING

    Izhevsk, 426009, Russia

  • Novartis Investigative Site

    RECRUITING

    Kemerovo, 650036, Russia

  • Novartis Investigative Site

    RECRUITING

    Khabarovsk, 680042, Russia

  • Novartis Investigative Site

    RECRUITING

    Khanty-Mansiysk, 628012, Russia

  • Novartis Investigative Site

    RECRUITING

    Khimky, 121552, Russia

  • Novartis Investigative Site

    RECRUITING

    Kirov, 610021, Russia

  • Novartis Investigative Site

    RECRUITING

    Krasnoyarsk, 660022, Russia

  • Novartis Investigative Site

    RECRUITING

    Moscow, 115304, Russia

  • Novartis Investigative Site

    RECRUITING

    Moscow, 115522, Russia

  • Novartis Investigative Site

    RECRUITING

    Moscow, 125284, Russia

  • Novartis Investigative Site

    RECRUITING

    Moscow, 129110, Russia

  • Novartis Investigative Site

    RECRUITING

    Moscow Region Balas, 143900, Russia

  • Novartis Investigative Site

    RECRUITING

    Perm, 614066, Russia

  • Novartis Investigative Site

    RECRUITING

    Pyatigorsk, 357502, Russia

  • Novartis Investigative Site

    RECRUITING

    Rostov-on-Don, 344006, Russia

  • Novartis Investigative Site

    RECRUITING

    Saint Petersburg, 194017, Russia

  • Novartis Investigative Site

    RECRUITING

    Saint Petersburg, 194291, Russia

  • Novartis Investigative Site

    RECRUITING

    Saint Petersburg, 197758, Russia

  • Novartis Investigative Site

    RECRUITING

    Saransk, 430032, Russia

  • Novartis Investigative Site

    RECRUITING

    Sestroretsk, 197706, Russia

  • Novartis Investigative Site

    RECRUITING

    Tver', 170008, Russia

  • Novartis Investigative Site

    RECRUITING

    Tyumen, 625023, Russia

  • Novartis Investigative Site

    RECRUITING

    Ufa, 450054, Russia

  • Novartis Investigative Site

    RECRUITING

    Vladikavkaz, 362002, Russia

  • Novartis Investigative Site

    RECRUITING

    Vladivostok, 690105, Russia

  • Novartis Investigative Site

    RECRUITING

    Volgograd, 400138, Russia

  • Novartis Investigative Site

    RECRUITING

    Voronezh, 394036, Russia

  • Novartis Investigative Site

    RECRUITING

    Yaroslavl, 150054, Russia

  • Novartis Investigative Site

    RECRUITING

    Yekaterinburg, 620036, Russia

  • Novartis Investigative Site

    RECRUITING

    Yuzhno-Sakhalinsk, 693010, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.